sponsored by Maple Ridge

Health & Fitness News Elsewhere  [fresh daily from the Web]


Merck's heart failure drug misses trial goals

Send a link to a friend

[June 06, 2009]  WHITEHOUSE STATION, N.J. (AP) -- Merck says its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.

InsuranceThe Whitehouse Station, N.J., company says rolofylline did not reach its primary or secondary goals in the late-stage trial. Merck & Co. is still analyzing study data but says it will not ask the Food and Drug Administration to approve the drug candidate this year.

The trial also showed that 30 mg rolofylline did not reduce the risk of death or hospitalization due to heart or kidney problems 60 days after treatment, and that it did not reduce kidney impairment. Merck will present full results from the PROTECT study at a future medical conference.

[Associated Press]

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Nursing Homes

Nursing Homes

< Recent articles

Back to top


 

News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries

Community | Perspectives | Law & Courts | Leisure Time | Spiritual Life | Health & Fitness | Teen Scene
Calendar | Letters to the Editor